Oncology

Emerging therapeutic options represent a new age for treatment of high-risk non–muscle invasive bladder cancer.

FDA fast track designation advances oral EP300/CBP inhibitor OPN-6602 for relapsed/refractory multiple myeloma, highlighting novel hematology-oncology options and key pharmacist considerations.

Students should consider reaching out to their experiential education department to learn what opportunities may be available.

Cristian Tomasetti, PhD, explains how obesity enlarges organs, raising cancer risk, and how GLP-1 weight loss therapy may reverse this, guiding oncology pharmacists.

In AML, sialylated CD43 blocks immune clearance beyond CD47, revealing new leukemia targets to boost macrophage phagocytosis.

TIL therapy offers a new metastatic melanoma option while FDA PDUFA dates reshape oncology approvals and planning.

This is the second complete response letter the manufacturer has received for this treatment regimen.

Keytruda Qlex is a subcutaneous formulation of pembrolizumab that offers a faster, more convenient alternative to IV administration with comparable efficacy.

ASCO guidelines reshape multiple myeloma care with quadruplet induction, earlier CAR T-cell therapy and bispecifics, and selective smoldering treatment.

Amy Seung outlines her priorities for leading HOPA through evolving therapies, workforce challenges, and expanding pharmacy roles.

Phase 3 trial data show that isatuximab quadruplet improves MRD negativity in transplant-eligible patients with multiple myeloma.

Pacritinib bridges high-risk myelofibrosis to allogeneic stem cell transplantation, preserving blood counts, shrinking spleen and symptoms, and enabling 95% of patients to undergo transplantation.

Air pollution exposure, particularly fine particulate matter and ozone, may worsen cardiac outcomes in patients with breast cancer receiving cardiotoxic therapies.

Waters Corporation's Onclarity HPV Self-Collection Kit represents a significant advance in expanding access to cervical cancer screening outside the clinic.

Phase 3 PATCH trial data show estrogen patches reduce hot flashes but raise gynecomastia risk.

Myelofibrosis model reveals malignant stem cells reprogram healthy support cells, fueling inflammation and fibrosis.

A pharmacist's guide to the most common cancer myths circulating online.

Octogenarians with early-stage non–small cell lung cancer (NSCLC) can safely undergo surgery and achieve survival and quality-of-life outcomes comparable to those of younger patients.

Team-based, multidisciplinary care aids personalized treatment, improving coordination across complex therapies, and enhances patient outcomes and long-term quality of life.

Circulating tumor DNA detected after neoadjuvant therapy may serve as a powerful biomarker for minimal residual disease and help predict breast cancer recurrence.

Selinexor plus ruxolitinib significantly improved spleen volume reduction in JAK inhibitor–naive myelofibrosis, supporting its potential as a novel frontline combination strategy.

New research identifies caspase-8 loss as a key driver of inflammatory reprogramming and tumor recurrence in small cell lung cancer.

Kelly Gable, PharmD, shares how empathy, presence, and practical guidance can transform patient experiences beyond the medication plan.

Alex Wolff, PharmD, BCOP, FHOPA, explains how patient populations, delivery models, and safety risks shape real-world implementation.

Gene and cell therapies are reshaping clinical workflows—and pharmacists are becoming essential guides in that shift.

Pharmacists and clinicians share strategies to streamline training, collaboration, and patient care with BTCEs.